Parkinson's disease: fetal cell or stem cell-derived treatments.

BMJ clinical evidence Pub Date : 2015-04-21

Arnar Astradsson, Tipu Z Aziz

{"title":"Parkinson's disease: fetal cell or stem cell-derived treatments.","authors":"Arnar Astradsson, Tipu Z Aziz","doi":"","DOIUrl":null,"url":null,"abstract":"Introduction: The mean age of onset of Parkinson's disease is about 65 years, with a median time of 9 years between diagnosis and death.Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of fetal cell or stem cell-derived therapy in people with Parkinson's disease? We searched: Medline, Embase, The Cochrane Library and other important databases up to September 2014 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).Results: We found two studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: fetal cell therapy versus deep brain stimulation; fetal cell therapy versus sham surgery; stem cell-derived therapy versus deep brain stimulation; stem cell-derived therapy versus sham surgery.","PeriodicalId":72432,"journal":{"name":"BMJ clinical evidence","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404982/pdf/2015-1203.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ clinical evidence","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The mean age of onset of Parkinson's disease is about 65 years, with a median time of 9 years between diagnosis and death.

Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of fetal cell or stem cell-derived therapy in people with Parkinson's disease? We searched: Medline, Embase, The Cochrane Library and other important databases up to September 2014 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Results: We found two studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.

Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: fetal cell therapy versus deep brain stimulation; fetal cell therapy versus sham surgery; stem cell-derived therapy versus deep brain stimulation; stem cell-derived therapy versus sham surgery.

本刊更多论文

帕金森氏症:胎儿细胞或干细胞衍生疗法。

帕金森病的平均发病年龄约为65岁，从诊断到死亡的中位时间为9年。方法和结果:我们进行了一项系统综述，旨在回答以下临床问题:胎儿细胞或干细胞衍生疗法对帕金森病患者的影响是什么?我们检索了截至2014年9月的Medline、Embase、The Cochrane Library等重要数据库(临床证据综述定期更新;请查看我们的网站获取最新版本的评论)。我们纳入了来自相关组织的危害警报，如美国食品和药物管理局(FDA)和英国药品和保健产品监管局(MHRA)。结果:我们发现两项研究符合我们的纳入标准。我们对干预措施的证据质量进行了GRADE评价。结论:在这篇系统综述中，我们提供了有关以下干预措施的有效性和安全性的信息:胎儿细胞治疗与深部脑刺激;胎儿细胞治疗与假手术;干细胞衍生疗法与深部脑刺激;干细胞衍生疗法与假手术。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMJ clinical evidence

自引率

0.00%

发文量